Ardsley Advisory Partners increased its holdings in shares of Akcea Therapeutics Inc (NASDAQ:AKCA) by 50.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 15,000 shares of the company’s stock after buying an additional 5,000 shares during the quarter. Ardsley Advisory Partners’ holdings in Akcea Therapeutics were worth $260,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of the stock. Geode Capital Management LLC raised its stake in Akcea Therapeutics by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 204,540 shares of the company’s stock worth $3,550,000 after buying an additional 3,147 shares during the period. Legal & General Group Plc acquired a new stake in Akcea Therapeutics during the 3rd quarter worth $111,000. Deutsche Bank AG raised its stake in Akcea Therapeutics by 17.4% during the 4th quarter. Deutsche Bank AG now owns 34,624 shares of the company’s stock worth $600,000 after buying an additional 5,134 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Akcea Therapeutics during the 3rd quarter worth $180,000. Finally, SG Americas Securities LLC acquired a new stake in Akcea Therapeutics during the 4th quarter worth $121,000. 29.14% of the stock is currently owned by institutional investors and hedge funds.
Several analysts recently commented on the company. BidaskClub raised Akcea Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, March 6th. Zacks Investment Research downgraded Akcea Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, March 1st. BMO Capital Markets raised their price objective on Akcea Therapeutics from $25.00 to $30.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 27th. Stifel Nicolaus downgraded Akcea Therapeutics from a “buy” rating to a “hold” rating and set a $20.00 price objective on the stock. in a research note on Tuesday, February 27th. Finally, Cowen downgraded Akcea Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. Akcea Therapeutics presently has an average rating of “Hold” and an average target price of $24.00.
WARNING: “Akcea Therapeutics Inc (AKCA) Shares Bought by Ardsley Advisory Partners” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://sportsperspectives.com/2018/03/14/akcea-therapeutics-inc-akca-shares-bought-by-ardsley-advisory-partners.html.
About Akcea Therapeutics
Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).
Want to see what other hedge funds are holding AKCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Akcea Therapeutics Inc (NASDAQ:AKCA).
Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.